SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: thebeach who wrote (1318)1/28/2000 12:18:00 PM
From: Jibacoa  Read Replies (2) of 2344
 
BIOM is correcting as expected. My average share cost has continued to come down, and I will continue to sell on "spikes" and keep ACCUMULATING it on any dips. The longer term future of BIOM remains GOOD, with an 80 to 90% probability of FDA approval of THERATOPE in one to two years and the further drugs it has on the "pipe-line" (BLP-25, etc)

As for Procyonbiopharma, I am glad that they got the first million of the 3 million private placement and that they are planning on starting human tests later this year. The pay-out of their research,however, seems to me a little bit too distant for me to wait for myself. Maybe I will buy some latter for my grandchildren.

Good luck to all.

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News